The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 760-762

  Wallentin, Lars ^a   Becker, Richard C ^b   James, Stefan K ^a   Harrington, Robert A ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DATA BASE; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GOOD CLINICAL PRACTICE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; ST SEGMENT ELEVATION; STENT THROMBOSIS; STROKE; SURVIVAL RATE; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; EUROPE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RESEARCH DESIGN; SURVIVAL RATE; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 79953671263     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0162     Document Type: Article

References (20)

1. Anderson JL, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-304.
2. Antman EM, et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
3. Bassand JP, Hamm C. New European guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction--what are the new and key messages. Polskie Arch Med Wewnetrznej 2007; 117: 391-393.
4. Van de Werf F, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
5. Prasad A, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 477-486.
6. Yusuf S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
7. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
8. Held C, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011; 57: 672-684.
9. Steg PG, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141.
10. Storey RF, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
11. James S, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067.
12. James S, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006-3016.
13. Wallentin L, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
14. Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
15. Serebruany VL. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
16. James S, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
17. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
18. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
19. Yusuf S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
20. Stone GW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.